November 8, 2024) - Rigrodsky Law, P.A. is investigating Avid Bioservices, Inc. ("Avid") (NASDAQ CM: CDMO) regarding possible breaches of fiduciary duties and other violations of law related to Avid's ...

Mason Capital opposes Grifols sale to Brookfield Asset Management, raising concerns about the potential acquisition in the ...

The banking industry is expected to win big as former President Donald Trump returns to the White House, ushering in ...

PE Hub has spotted seven private equity deals involving franchises in the past six months. Here’s a look at the deals, ...

Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Avid Bioservices, Inc. (NASDAQ: CDMO) to ...

Funds managed by GHO Capital Partners LLP and Ampersand Management LLC agreed to acquire the company, and it will continue to ...

Rowley Law PLLC is investigating potential securities law violations by Avid Bioservices, Inc. and its board of directors concerning the proposed acquisition of the company by GHO Capital Partners LLP ...

The merger agreement is valued at approximately $1.1 billion. Avid Bioservices, a biologics contract development and manufacturing organization (CDMO), announced on Nov. 6, 2024 that it has entered ...

Avid Bioservices shares were up 12% at $12.25 after getting a buyout offer from GHO Capital Partners and Ampersand Capital Partners. Under the terms of the buyout, Avid will be acquired by funds ...

Just days after laying out $90 million to acquire Nektar Therapeutics’ Alabama manufacturing plant, Ampersand Capital ...

Avid Bioservices (CDMO) has agreed to be acquired by GHO Capital Partners and Ampersand Capital Partners through a cash deal that values the company at $1.1B. Read more here.

The definitive merger agreement stipulates that GHO and Ampersand will purchase all outstanding shares of Avid.